

VENXXIVA- tiopronin tablet, delayed release

Cycle Pharmaceuticals Ltd.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VENXXIVA™ safely and effectively. See full prescribing information for VENXXIVA.

VENXXIVA (tiopronin) delayed-release tablets, for oral use
Initial U.S. Approval: 1988

INDICATIONS AND USAGE

VENXXIVA is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. (1)

DOSAGE AND ADMINISTRATION

- The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day. (2.1)
- The recommended initial dosage in pediatric patients 9 years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients. (5.1, 8.4)
- Measure urinary cystine 1 month after initiation of VENXXIVA and every 3 months thereafter. (2.3)
- Administer VENXXIVA in 3 divided doses at the same times each day, without food. (2.1)

DOSAGE FORMS AND STRENGTHS

Tablets: 100 mg and 300 mg (3)

CONTRAINDICATIONS

- Hypersensitivity to tiopronin or any component of VENXXIVA (4)

WARNINGS AND PRECAUTIONS

- Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. (2.1, 5.1, 8.4)
- Hypersensitivity reactions have been reported during tiopronin treatment. (4, 5.2)

ADVERSE REACTIONS

Most common adverse reactions ($\geq 10\%$) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-857-437-3969 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Lactation: Breastfeeding is not recommended. (8.2)
- Geriatric: Choose dose carefully and monitor renal function in the elderly. (8.5)

Additional pediatric use information is approved for Mission Pharmacal Company's Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Company's marketing exclusivity rights, this drug product is not labeled with that information.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

2.3 Monitoring

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Proteinuria

5.2 Hypersensitivity Reactions

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Alcohol

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

VENXXIVA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.

Additional pediatric use information is approved for Mission Pharmacal Company's Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Company's marketing exclusivity rights, this drug product is not labeled with that information.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

Adults: The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day.

Pediatrics: The recommended initial dosage in pediatric patients 9 years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients [see *Warnings and Precautions (5.1), Use in Specific Populations (8.4)*].

Administer VENXXIVA in 3 divided doses at the same times each day, without food.

Consider starting VENXXIVA at a lower dosage in patients with history of severe toxicity to d-penicillamine.

Additional pediatric use information is approved for Mission Pharmacal Company's Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Company's marketing exclusivity rights, this drug product is not labeled with that information.

2.3 Monitoring

Measure urinary cystine 1 month after starting VENXXIVA and every 3 months thereafter. Adjust VENXXIVA dosage to maintain urinary cystine concentration less than 250 mg/L.

Assess for proteinuria before treatment and every 3 to 6 months during treatment [see *Warnings and Precautions (5.1)*].

Discontinue VENXXIVA in patients who develop proteinuria, and monitor urinary protein and renal function. Consider restarting VENXXIVA treatment at a lower dosage after resolution of proteinuria.

3 DOSAGE FORMS AND STRENGTHS

Tablets for oral use:

100 mg tablets: White to off-white, round shaped, enteric coated tablets imprinted with "1A" with black ink on one side and plain on other side, free from physical defects.

300 mg tablets: White to off-white, round shaped, enteric coated tablets imprinted with "3A" with black ink on one side and plain on other side, free from physical defects.

4 CONTRAINDICATIONS

VENXXIVA is contraindicated in patients with hypersensitivity to tiopronin or any other components of VENXXIVA [see *Warnings and Precautions (5.2)*].

5 WARNINGS AND PRECAUTIONS

5.1 Proteinuria

Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. [see *Dosage and Administration (2.3)*, *Adverse Reactions (6.1, 6.2)*, *Use in Specific Populations (8.4)*].

Monitor patients for the development of proteinuria and discontinue therapy in patients who develop proteinuria [see *Dosage and Administration (2.3)*].

5.2 Hypersensitivity Reactions

Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported [see *Contraindications (4)*].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Proteinuria [see *Warnings and Precautions (5.1)*]
- Hypersensitivity [see *Warnings and Precautions (5.2)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of the drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions occurring at an incidence of $\geq 5\%$ in an uncontrolled trial in 66 patients with cystinuria age 9 to 68 years are shown in the table below. Patients in group 1 had previously been treated with d-penicillamine; those in group 2 had not. Of those

patients who had stopped taking d-penicillamine due to toxicity (34 out of 49 patients in group 1), 22 were able to continue treatment with tiopronin. In those without prior history of d-penicillamine treatment, 6% developed reactions of sufficient severity to require tiopronin withdrawal.

Table 1 presents adverse reactions $\geq 5\%$ in either treatment group occurring in this trial.

Table 1: Adverse Reactions Occurring in One or More Patients

System Organ Class	Adverse Reaction	Group 1 Previously treated with d- penicillamine (N = 49)	Group 2 Naïve to d- penicillamine (N = 17)
Blood and Lymphatic System Disorders	anemia	1 (2%)	1 (6%)
Gastrointestinal Disorders	nausea	12 (25%)	2 (12%)
	emesis	5 (10%)	-
	diarrhea/soft stools	9 (18%)	1 (6%)
	abdominal pain	-	1 (6%)
	oral ulcers	6 (12%)	3 (18%)
General Disorders and Administration Site Conditions	fever	4 (8%)	-
	weakness	2 (4%)	2 (12%)
	fatigue	7 (14%)	-
	peripheral (edema)	3 (6%)	1 (6%)
	chest pain	-	1 (6%)
Metabolism and Nutrition Disorders	anorexia	4 (8%)	-
Musculoskeletal and Connective Tissue Disorders	arthralgia	-	2 (12%)
Renal and Urinary Disorders	proteinuria	5 (10%)	1 (6%)
	impotence	-	1 (6%)
Respiratory, Thoracic and Mediastinal Disorders	cough	-	1 (6%)
Skin and Subcutaneous Tissue Disorders	rash	7 (14%)	2 (12%)
	ecchymosis	3 (6%)	-
	pruritus	2 (4%)	1 (6%)
	urticaria	4 (8%)	-
	skin wrinkling	3 (6%)	1 (6%)

Taste Disturbance

A reduction in taste perception may develop. It is believed to be the result of chelation of trace metals by tiopronin. Hypogeusia is often self-limited.

6.2 Postmarketing Experience

Adverse reactions have been reported from the literature, as well as during post-approval use of tiopronin. Because the post-approval reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to tiopronin exposure.

Adverse reactions reported during the postmarketing use of tiopronin are listed by body system in **Table 2**.

Table 2: Adverse Reactions Reported for Tiopronin Pharmacovigilance by System Organ Class and Preferred Term

System Organ Class	Preferred Term
Cardiac Disorders	congestive heart failure
Ear and Labyrinth Disorder	vertigo
Gastrointestinal Disorders	abdominal discomfort; abdominal distension; abdominal pain; chapped lips; diarrhea; dry mouth; dyspepsia; eructation; flatulence; gastrointestinal disorder; gastroesophageal reflux disease; nausea; vomiting; jaundice; liver transaminitis
General Disorders and Administration Site Conditions	asthenia; chest pain; fatigue; malaise; pain; peripheral swelling; pyrexia; swelling
Investigations	glomerular filtration rate decreased; weight increased
Metabolism and Nutrition Disorders	decreased appetite; dehydration; hypophagia
Musculoskeletal and Connective Tissue Disorders	arthralgia; back pain; flank pain; joint swelling; limb discomfort; musculoskeletal discomfort; myalgia; neck pain; pain in extremity
Nervous System Disorders	ageusia; burning sensation; dizziness; dysgeusia; headache; hypoesthesia
Renal and Urinary Disorders	nephrotic syndrome; proteinuria; renal failure
Skin and Subcutaneous Tissue Disorders	dry skin; hyperhidrosis; pemphigus foliaceus; pruritus; rash; rash pruritic; skin irritation; skin texture abnormal; skin wrinkling; urticaria

7 DRUG INTERACTIONS

7.1 Alcohol

Tiopronin is released faster from VENXXIVA in the presence of alcohol and the risk for adverse events associated with VENXXIVA when taken with alcohol is unknown. Avoid alcohol consumption 2 hours before and 3 hours after taking VENXXIVA [see *Clinical*

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available published case report data with tiopronin have not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse pregnancy outcomes (see *Clinical Considerations*). In animal reproduction studies, there were no adverse developmental outcomes with oral administration of tiopronin to pregnant mice and rats during organogenesis at doses up to 2 times a 2 grams/day human dose (based on mg/m²). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Renal stones in pregnancy may increase the risk of adverse pregnancy outcomes, such as preterm birth and low birth weight.

Data

Animal Data

No findings of fetal malformations could be attributed to the drug in reproduction studies in mice and rats at doses up to 2 times the highest recommended human dose of 2 grams/day (based on mg/m²).

8.2 Lactation

Risk Summary

There are no data on the presence of tiopronin in either human or animal milk or on the effects of the breastfed child. A published study suggests that tiopronin may suppress milk production. Because of the potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not recommended during treatment with VENXXIVA.

8.4 Pediatric Use

VENXXIVA is indicated in pediatric patients 9 years of age and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation who are not responsive to these measures alone. This indication is based on safety and efficacy data from a trial in patients 9 years to 68 years of age and clinical experience. Proteinuria, including nephrotic syndrome, has been reported in pediatric patients. Pediatric patients receiving greater than 50 mg/kg tiopronin per day may be at greater risk [see *Dosage and Administration* (2.1, 2.3), *Warnings and Precautions* (5.1) and *Adverse Reactions* (6.1)].

VENXXIVA tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients unable to swallow tablets [see *Dosage and Administration* (2.1)].

Additional pediatric use information is approved for Mission Pharmacal Company's Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Company's marketing exclusivity rights, this drug product is not labeled with that information.

8.5 Geriatric Use


This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

10 OVERDOSAGE

There is no information on overdosage with tiopronin.

11 DESCRIPTION

VENXXIVA (tiopronin) delayed-release tablets are a reducing and cystine-binding thiol drug (CBTD) for oral use. Tiopronin is N-(2-Mercaptopropionyl) glycine and has the following structure:



Tiopronin has the empirical formula $\text{C}_5\text{H}_9\text{NO}_3\text{S}$ and a molecular weight of 163.19. In this drug product tiopronin exists as a dl racemic mixture.

Tiopronin is a white to off-white color crystalline powder, which is freely soluble in water.

Each VENXXIVA tablet contains 100 or 300 mg of tiopronin. The inactive ingredients in VENXXIVA tablets include lactose monohydrate, low substitute hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, hypromellose 2910, methacrylic acid: ethyl acrylate copolymer (Eudragit L 100-55), talc, triethyl citrate. The imprinting ink contains shellac, ferrousferic oxide and propylene glycol.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.

12.2 Pharmacodynamics

The decrement in urinary cystine produced by tiopronin is generally proportional to the dose. A reduction in urinary cystine of 250 to 350 mg/day at tiopronin dosage of 1 g/day, and a decline of approximately 500 mg/day at a dosage of 2 g/day, might be expected. Tiopronin has a rapid onset and offset of action, showing a fall in cystine excretion on the first day of administration and a rise on the first day of drug withdrawal.

12.3 Pharmacokinetics

Absorption

VENXXIVA Tablets

When tiopronin IR and VENXXIVA single doses were given to fasted healthy subjects,

the median time to peak plasma levels (T_{max}) was 1 (range: 0.5 to 2.1) and 3 (range: 1.0 to 6.0) hours, respectively. The peak exposure (C_{max}) and total exposure (AUC_{0-t}) of tiopronin from VENXXIVA tablets were decreased by 22% and 7% respectively compared to tiopronin IR tablets.

Elimination

Excretion

When tiopronin is given orally, up to 48% of dose appears in urine during the first 4 hours and up to 78% by 72 hours.

Drug Interactions

Alcohol

An *in vitro* dissolution study was conducted to evaluate the impact of alcohol (5, 10, 20, and 40%) on the dose dumping of VENXXIVA tablets. The study results showed that the addition of alcohol to the dissolution media increases the dissolution rate of VENXXIVA tablets in the acidic media of 0.1N HCl [see *Drug Interactions (7.1)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Long-term carcinogenicity studies in animals have not been performed.

Mutagenesis

Tiopronin was not genotoxic in the chromosomal aberration, sister chromatid exchange, and *in vivo* micronucleus assays.

Impairment of Fertility

High doses of tiopronin in experimental animals have been shown to interfere with maintenance of pregnancy and viability of the fetus. In 2 published male fertility studies in rats, tiopronin at 20 mg/kg/day intramuscular (IM) for 60 days induced reductions in testis, epididymis, vas deferens, and accessory sex glands weights and in the count and motility of cauda epididymal sperm.

16 HOW SUPPLIED/STORAGE AND HANDLING

100 mg delayed-release, white to off-white, round shaped, enteric-coated tablets imprinted with "1A" with black ink on one side and plain on other side, free from physical defects.

Bottles of 300 with child-resistant closure, **NDC 70709-121-30**.

300 mg delayed-release, white to off-white, round shaped, enteric-coated tablets imprinted with "3A" with black ink on one side and plain on other side, free from physical defects.

Bottles of 90 with child-resistant closure, **NDC 70709-123-90**.

Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see *USP Controlled Room Temperature*].

17 PATIENT COUNSELING INFORMATION

Lactation

Advise women that breastfeeding is not recommended during treatment with VENXXIVA [see *Use in Specific Populations (8.2)*].

Manufactured for:



Distributed by:

Cycle Pharmaceuticals Ltd, Cambridge, CB3 0FA, UK

Revised: December 2024

PRINCIPAL DISPLAY PANEL

100 mg - 300 Tablets

Each delayed-release tablet contains 100 mg of Tiopronin

Rx only. Usual Dosage:
See Prescribing Information.

This package is child-resistant. Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

Keep this and all medications out of the reach of children.

Mfg. Lic. No. : 22/SRD/TS/2017/F/G

Manufactured for:
Torrent Pharmaceuticals Limited, India

Distributed by:
Cycle Pharmaceuticals Ltd
Cambridge, CB3 0FA, UK

300 Tablets NDC 70709-121-30

VENXXIVA™
(tiopronin)
delayed-release
tablets

100 mg

Rx only

3 70709 12130 7

SPM1017-R01

NVZ AREA
45 X 22 mm

300 mg - 90 Tablets

Each delayed-release tablet contains 300 mg of Tiopronin

Rx only. Usual Dosage:
See Prescribing Information.

This package is child-resistant. Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

Keep this and all medications out of the reach of children.

Mfg. Lic. No. : 22/SRD/TS/2017/F/G

Manufactured for:
Torrent Pharmaceuticals Limited, India

Distributed by:
Cycle Pharmaceuticals Ltd
Cambridge, CB3 0FA, UK

90 Tablets NDC 70709-123-90

VENXXIVA™
(tiopronin)
delayed-release
tablets

300 mg

Rx only

3 70709 12390 5

SPM1018-R01

NVZ AREA
45 X 22 mm

VENXXIVA

tiopronin tablet, delayed release

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70709-121
Route of Administration	ORAL		

Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
TIOPRONIN (UNII: C5W04GO61S) (TIOPRONIN - UNII:C5W04GO61S)		TIOPRONIN	100 mg	
Inactive Ingredients				
Ingredient Name			Strength	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)				
HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH)				
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)				
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)				
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)				
TALC (UNII: 7SEV7J4R1U)				
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)				
MAGNESIUM STEARATE (UNII: 70097M6I30)				
Product Characteristics				
Color	WHITE (white to off-white)	Score	no score	
Shape	ROUND	Size	8mm	
Flavor		Imprint Code	1A	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70709-121-30	300 in 1 BOTTLE; Type 0: Not a Combination Product	01/22/2025	
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA216990	01/22/2025		

VENXXIVA			
tiopronin tablet, delayed release			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70709-123
Route of Administration	ORAL		
Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
TIOPRONIN (UNII: C5W04GO61S) (TIOPRONIN - UNII:C5W04GO61S)		TIOPRONIN	300 mg
Inactive Ingredients			
Ingredient Name			Strength
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)			

HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH)	
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED (UNII: 2165RE0K14)	
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)	
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)	
TALC (UNII: 7SEV7J4R1U)	
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	

Product Characteristics

Color	WHITE (white to off-white)	Score	no score
Shape	ROUND	Size	11mm
Flavor		Imprint Code	3A
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70709-123-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	01/22/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA216990	01/22/2025	

Labeler - Cycle Pharmaceuticals Ltd. (218215530)

Establishment

Name	Address	ID/FEI	Business Operations
Optimus Pharma Private Limited		675474672	MANUFACTURE(70709-121, 70709-123)

Revised: 12/2024

Cycle Pharmaceuticals Ltd.